Spots Global Cancer Trial Database for IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
Official Title: A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors
Study ID: NCT03665129
Conditions
Interventions
Study Description
Brief Summary: This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
James Graham Brown Cancer Center, Louisville, Kentucky, United States
Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
ICAHN School of Medicine at Mount Sinai, New York, New York, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
NEXT Oncology, San Antonio, Texas, United States
Centre Georges-Francois Leclerc, Dijon, , France
Centre Leon Berard, Lyon, , France
Hôpital de la Timone- AP-HM, Marseille, , France
Institut du Cancer de Montpellier, Montpellier, , France
Centre Hospitalier Universitaire- Hôpital Nord Laennec, Nantes, , France
Centre Eugène Marquis, Rennes, , France
Institut Gustave Roussy, Villejuif, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
